Arachidonoyl Glycine-d8 – 100 µg

Brand:
Cayman
CAS:
1159908-44-7
Storage:
-20
UN-No:
De Minimis - 1170 / 3

Arachidonoyl glycine-d8 (NAGly-d8) contains eight deuterium atoms at the 5, 6, 8, 9, 11, 12, 14, and 15 positions. It is intended for use as an internal standard for the quantification of NAGly by GC- or LC-mass spectrometry. NAGly has been isolated from cell cultures treated with arachidonoyl ethanolamide (AEA),{9578} from extracts of mammalian brain,{9579,9589} and has also been synthesized as an analog of AEA for structure/activity testing.{9580} NAGly may be produced endogenously via oxidation of AEA, or by transacylation of arachidonoyl coenzyme A. NAGly is reported to have analgesic activities in whole animal experiments.{9578,9579,9589} Since it seems to be a very poor ligand for the CB1 receptor,{9580} these effects are probably mediated via other signalling pathways.  

 

Available on backorder

SKU: 10007531 - 100 µg Category:

Description

An internal standard for the quantification of NAGly by GC- or LC-MS


Formal name: N-[1-oxo-5Z,8Z,11Z,14Z-eicosatetraenyl]-glycine,5,6,8,9,11,12,14,15-d8

Synonyms:  N-Arachidonyl Glycine-d8|NAGly-d8

Molecular weight: 369.6

CAS: 1159908-44-7

Purity: ≥99% deuterated forms (d1-d8)

Formulation: A solution in ethanol


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Lipids|Fatty Amides||Research Area|Lipid Biochemistry|Endocannabinoid/Endocannabinoid-like||Research Area|Neuroscience|Cannabinoid Research|Endocannabinoids||Research Area|Neuroscience|Pain Research